Clinical Trials Logo

Inflammatory Bowel Disease clinical trials

View clinical trials related to Inflammatory Bowel Disease.

Filter by:

NCT ID: NCT06405503 Not yet recruiting - Clinical trials for Inflammatory Bowel Disease

Impact of Primary Language on Treatment and Outcomes in Inflammatory Bowel Disease

Start date: June 1, 2024
Phase:
Study type: Observational

A thorough discussion of treatment options to manage inflammatory bowel disease (IBD), including the risks and benefits of each class of medication, can be a complex discussion and time consuming. Having to use a translator adds an additional layer of time and complexity to these discussions as well as potential misunderstanding. Further, in addition to language, cultural differences can also play into treatment acceptance. This study aims to determine the impact of primary language on the selection of treatment for IBD and on disease outcomes.

NCT ID: NCT06346288 Recruiting - Clinical trials for Inflammatory Bowel Disease

A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

Start date: May 6, 2024
Phase: Phase 4
Study type: Interventional

Inflammatory bowel disease (IBD) is a chronic inflammatory disease that requires lifelong treatment. This study will asses the concentrations of risankizumab in the breast milk of lactating women with IBD Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and Crohn's Disease. This is an open-label milk-only study lactation study to evaluate the presence of risankizumab in the milk of lactating women. Approximately 10 adult lactating women with IBD will be enrolled from approximately 3 sites in Israel and or the United States. Participants will receive risakizumab maintenance therapy every 8 weeks postpartum prior to start of participation in this study. The study duration is approximately 7 months. Participants will attend regular visits during the study at a hospital or clinic. The participants will also be completing questionnaires and will have medical assessments, checking for side effects.

NCT ID: NCT06321887 Recruiting - Clinical trials for Inflammatory Bowel Disease

EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD

CAESAR
Start date: October 20, 2023
Phase: Phase 3
Study type: Interventional

Iron deficiency anaemia (IDA) is common in inflammatory bowel disease (IBD). However, although iron is commonly prescribed, the amount of elemental iron needed to achieve clinical efficacy, and the optimal method of supplementation, are under debate. This pilot study aims to investigate the efficacy and safety of low dose and standard dose oral iron preparations for the treatment of IDA in patients with IBD.

NCT ID: NCT06175949 Not yet recruiting - Clinical trials for Inflammatory Bowel Disease

A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses of HRS-7085 Tablets in Healthy Subjects, With Assessment of Food Effects

Start date: December 2023
Phase: Phase 1
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-parallel-controlled, Phase I clinical trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of HRS-7085 tablets in healthy subjects, with assessment of food effects

NCT ID: NCT06031038 Active, not recruiting - Ulcerative Colitis Clinical Trials

Impact of Telemonitoring in the Management of Complex IBD in Spain: M-TECCU

M-TECCU
Start date: July 1, 2020
Phase: N/A
Study type: Interventional

M-TECCU is a study: multicenter, randomized and open. It consists of two parallel groups to compare the efficacy of the TECCU web-based telemonitoring system to achieve and maintain activity remission in patients with moderate-high complexity inflammatory bowel disease compared to usual clinical practice.

NCT ID: NCT06001450 Recruiting - Pregnancy Clinical Trials

Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation

PLANET
Start date: August 30, 2023
Phase:
Study type: Observational

The PLANET Study aims to determine the impact of microplastics on intestinal inflammation and gut microbiome in order to understand the role of this pollutant on the risk of developing inflammatory bowel disease (IBD) as well as other diseases. With this information, the researchers hope to characterize better the role of environmental pollutants on IBD and develop novel strategies towards prevention.

NCT ID: NCT05973500 Recruiting - Clinical trials for Inflammatory Bowel Disease

Effect of Mediterranean Diet in Inflammatory Bowel Disease

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The effects of diet on inflammatory bowel disease is an under-studied area of research. The investigators are interested in further investigating the role that diet contributes to inflammatory bowel disease severity. The investigators will collect blood and stool samples from patients with inflammatory bowel disease (IBD) before and after diet changes. The stool samples will be analyzed using metabolomics and microbiome analysis to determine changes after the new diet has been implemented. The investigators will then compare changes in the patient's overall disease state by measuring markers of inflammation including C-reactive protein (CRP) and fecal calprotectin to determine how this diet affects the disease state.

NCT ID: NCT05659953 Not yet recruiting - Crohn Disease Clinical Trials

LMT503 First-in-human SAD, MAD, and FE Study

Start date: April 1, 2024
Phase: Phase 1
Study type: Interventional

This is a double-blind, randomized, placebo-controlled study, consisting of a single ascending dose (SAD) part with integrated food effect (FE) arm, and a multiple ascending dose (MAD) part to assess the safety, tolerability, and PK of ascending single and multiple oral doses of LMT503. The study will start with the SAD part.

NCT ID: NCT05652491 Withdrawn - Ulcerative Colitis Clinical Trials

The Role of Gut Microbiome in Predicting Comorbidities and Complications in Children With Inflammatory Bowel Disease

Start date: December 9, 2022
Phase:
Study type: Observational

Background: Bacteria and other microorganisms that live in the intestines (the gut microbiome) play an important role in a person s health. The gut microbiome helps to regulate the immune system and control inflammation. Imbalances in the gut microbiome have been linked to illnesses such as inflammatory bowel disease (IBD). People diagnosed with IBD can have serious health problems. Researchers want to know more about how the gut microbiome affects the development and progression of IBD in children. In this natural history study, they will compare the gut microbiomes of healthy children with those who have IBD. Objective: To collect stool and samples of intestine tissue from children with and without IBD undergoing colonoscopy. Eligibility: People under 21 years old who are having a colonoscopy at the Inova Health System or Pediatric Specialists of Virginia. Design: Participants will fill out a questionnaire. They will answer questions about their history. Topics may include how they were fed as infants; how they were born; and how often they took antibiotics. Stool and tissue samples from the intestines will be taken during the participants colonoscopy. They may also give samples of blood and urine. Participants may be asked to provide additional stool, blood, and urine samples. They may do this up to 3 times per year. These samples may be collected at the clinic; they may also be collected at home and mailed to the researchers. If they have more colonoscopies, participants may be asked for more tissue samples. Participants will be enrolled for up to 10 years. ...

NCT ID: NCT05638347 Completed - Clinical trials for Inflammatory Bowel Disease

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect.

Start date: December 5, 2022
Phase: Phase 1
Study type: Interventional

The study is being conducted to evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of HRS-7085.